An experienced team and a thoughtful, research-driven investment approach create a compelling healthcare offering for investors willing to stomach some volatility. It earns Above Average People and Process ratings.
PGIM Jennison Health Sciences Fund- Class A PHLAX
- NAV / 1-Day Return 39.49 / +0.74 %
- Total Assets 1.5B
-
Adj. Expense Ratio
1.150%
- Expense Ratio 1.150%
- Distribution Fee Level Below Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Blend
- Min. Initial Investment 1,000
- Status Open
- TTM Yield 0.11%
- Turnover 81%
USD | NAV as of Aug 08, 2026 | 1-Day Return as of Aug 08, 2026, 12:11 AM GMT+0
Morningstar’s Analysis PHLAX
Will PHLAX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 53.2
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Eli Lilly and Co | 17.59 | 261M | Healthcare |
Merck & Co Inc | 6.13 | 91M | Healthcare |
UnitedHealth Group Inc | 5.99 | 89M | Healthcare |
Thermo Fisher Scientific Inc | 4.33 | 64M | Healthcare |
Prudential Govt Money Mkt Fd | 4.28 | 64M | Cash and Equivalents |
argenx SE ADR | 3.69 | 55M | Healthcare |
Vertex Pharmaceuticals Inc | 3.49 | 52M | Healthcare |
Danaher Corp | 3.26 | 48M | Healthcare |
CVS Health Corp | 3.07 | 46M | Healthcare |
Lonza Group Ltd | 2.98 | 44M | Healthcare |
United States